Insulin efsitora alfa (efsitora) is a new basal insulin designed for once-weekly administration. Data on safety and efficacy have been limited to small, phase 1 or phase 2 trials. We conducted a ...

Please provide your email address to receive an email when new articles are posted on . The FDA recently extended the regulatory review period for a fixed combination of insulin degludec and ...

Degludec vs glargine in type 2 diabetes Degludec is noninferior to glargine regarding the incidence of major cardiovascular events among patients with type 2 diabetes. Steven P. Marso, MD, from the ...

Once-weekly efsitora noninferior to once-daily degludec for decrease in mean glycated hemoglobin level. (HealthDay News) — Once-weekly efsitora is noninferior to once-daily degludec for reducing ...

Degludec is an ultralong-acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-to-day ...

San Diego, CA - The new longer-acting diabetes drug insulin degludec (Novo Nordisk) improves long-term glycemic control with a lower rate of nocturnal hypoglycemia compared with insulin glargine ...

The European Commission approved an expanded use for a fixed combination of insulin degludec and liraglutide for adults with type 2 diabetes and renal impairment, Novo Nordisk announced in a press ...

Bagsværd, Denmark, 28 April 2022 – Novo Nordisk today announced headline results from the ONWARDS 2 trial, a phase 3a, 26-week efficacy and safety treat-to-target trial investigating once-weekly ...

BARCELONA — Insulin degludec (Tresiba, Novo Nordisk) didn't reduce overall hypoglycemic events compared with insulin glargine U300 (Toujeo, Sanofi) in a head-to-head trial of the two second-generation ...

Review of Insulin degludec plus liraglutide as a medical therapy provided no hint of added benefit in type 2 diabetes due to lack of suitable studies. The fixed-ratio combination of the two drugs ...

This material is intended for UK medical media only. For journalistic assessment and preparation before publication. New findings show that Xultophy® (insulin degludec/liraglutide; IDegLira), the ...

Novo Nordisk today announced that the Japanese Ministry of Health, Labour and Welfare has approved Tresiba® (insulin degludec) for the treatment of diabetes. Tresiba® is a new generation of once-daily ...